Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance

Autor: Saptha Vijayan, Tabasum Sidiq, Peter J. van den Elsen, Koichi Kobayashi, Suhail Yousuf
Rok vydání: 2019
Předmět:
Zdroj: Vijayan, S, Sidiq, T, Yousuf, S, van den Elsen, P J & Kobayashi, K S 2019, ' Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance ', Immunogenetics, vol. 71, no. 3, pp. 273-282 . https://doi.org/10.1007/s00251-019-01106-z
ISSN: 1432-1211
0093-7711
Popis: Major histocompatibility complex (MHC) class I and class II molecules play critical roles in the activation of the adaptive immune system by presenting antigens to CD8+ and CD4+ T cells, respectively. Although it has been well known that CIITA (MHC class II transactivator), an NLR (nucleotide-binding domain, leucine-rich-repeat containing) protein, as a master regulator of MHC class II gene expression, the mechanism of MHC class I gene transactivation was unclear. Recently, another NLR protein, NLRC5 (NLR family, CARD domain-containing 5), was identified as an MHC class I transactivator (CITA). NLRC5 is a critical regulator for the transcriptional activation of MHC class I genes and other genes involved in the MHC class I antigen presentation pathway. CITA/NLRC5 plays a crucial role in human cancer immunity through the recruitment and activation of tumor killing CD8+ T cells. Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
Databáze: OpenAIRE
Externí odkaz: